·The Hindu·15 marks·250–350 wordsEnvironmentS&T

Centralised scrutiny of drug approvals strengthens safety but strains cooperative federalism. Examine in the context of India's drug regulation.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. How centralised scrutiny strengthens safety
  2. How it strains cooperative federalism
  3. Way forward

"Drugs and poisons" is on the Concurrent List. Under the Drugs and Cosmetics Act, 1940, the Centre (through CDSCO) approves new drugs, while State drug authorities license their manufacture and sale. The Health Ministry's draft to bring all antimicrobials under the 'New Drug' definition of the NDCT Rules, 2019 [1] moves power further to the Centre. It does strengthen safety, but it puts pressure on the shared nature of drug regulation.

How centralised scrutiny strengthens safety

  • Closes the licensing gap: some antimicrobial products are now licensed without adequate regulatory scrutiny. Under the draft, central approval would be needed before any manufacturing licence [1].
  • One standard for all: a single central checkpoint can be kept consistent more easily than 36 State standards. This matters for antimicrobial resistance (AMR), because one bad approval spreads resistance across the country.
  • Expert backing: the 2013 Standing Committee recommended centralised licensing of drug manufacture because drug-control systems were weak [3]. The Mashelkar Committee made a similar recommendation earlier.
  • Traceability: a separate licence for selling bulk drugs (APIs, the active ingredients) under the Drugs Rules, 1945 brings oversight to the API trade [1].

How it strains cooperative federalism

  • States lose ground: States already hold licensing powers. Moving approval to the Centre turns them into implementers rather than co-regulators.
  • The Centre is stretched too: the 59th Standing Committee Report (2012) found lapses in CDSCO's own approval process [2]. The 2013 committee found weak infrastructure at both levels [3]. Sending more files to the Centre can mean slower decisions, not better ones.
  • Uneven effects: delays hurt generic makers, especially MSMEs, which are concentrated in a few States. This hits State revenue and jobs.
  • Rules made by notification: major changes come through subordinate rules rather than parliamentary debate. States have little formal say beyond the advisory Drugs Consultative Committee (DCC).

Way forward

  • Use the DCC as a real forum for co-decision before rules are notified.
  • Build CDSCO capacity and set approval deadlines, with joint Centre–State inspections.
  • Use digital single-window licensing, which keeps the Centre's standards while State licensing continues.

In AMR, the Centre and the States need each other. The Centre should set the standards, and States should keep implementing and enforcing them. If the Centre adds capacity and consults States through the DCC, it can deliver NAP-AMR 2.0's safety goals and protect cooperative federalism at the same time.

Sources

  1. 1Ministry seeks tighter norms for antimicrobials, bulk trade — The Hindu, 20 Nov 2026draft adding antimicrobials to the 'New Drug' definition under the NDCT Rules, 2019; separate bulk-drug sale licence under the Drugs Rules, 1945; concern over licences granted without adequate scrutiny
  2. 259th Report of the Parliamentary Standing Committee on Health on the Functioning of CDSCO (2012) — PRS Legislative Researchlapses in the central drug-approval process
  3. 379th Report of the Standing Committee on Health on the Drugs and Cosmetics (Amendment) Bill, 2013 — PRS Legislative Researchrecommended centralised licensing of manufacture; weak drug-control infrastructure at the Centre and in the States
Practice
2 questions on this article
Check the answer for each question, or reveal all at once.
Practice MCQs →

More from this note

More on Environment